Merkel Cell Carcinoma Drug Pipeline — PatSnap Eureka
Merkel Cell Carcinoma Drug Pipeline: Checkpoint Inhibitors & Targeted Approaches
MCC is a rare, aggressive neuroendocrine skin malignancy driving urgent demand for novel systemic therapies. This analysis covers PD-1/PD-L1 blockade, LSD1 epigenetic inhibition, ADCs, and combination strategies across 15+ patent filings from Regeneron, BMS, Dana-Farber, and more.
A Biologically Distinctive Malignancy with a Rapidly Evolving IP Landscape
Merkel cell carcinoma is a rare, aggressive neuroendocrine skin malignancy with historically poor prognosis in advanced stages. Retrieved patent and literature records highlight PD-1/PD-L1 as the dominant therapeutic axis across rare and aggressive skin cancers, including MCC and cutaneous squamous cell carcinoma (CSCC). More than 15 distinct patent filings across multiple jurisdictions address PD-1 axis inhibition in skin cancers.
A key biological distinction sets MCC apart: unlike most cancers where high PD-L1 expression predicts poor prognosis, PD-L1 overexpression in MCC tumors is associated with favorable prognosis — a finding documented by Nagoya City University in patent filings. Furthermore, PD-L1 expression in primary MCC lesions does not correlate with prognosis, but expression in cutaneous metastatic lesions shows strong correlation, underscoring intra-tumoral heterogeneity as a critical challenge.
Beyond immunotherapy, retrieved records from leading life sciences IP holders including Regeneron, Bristol-Myers Squibb, Dana-Farber Cancer Institute, and Genmab implicate LSD1 (KDM1A), AXL, CD228, and MEK/MAPK pathway components as targets in the broader rare skin cancer landscape. Glucose-6-phosphate dehydrogenase (G6PD) expression has also been identified as an independent prognostic marker in skin cancer, with high G6PD correlating with poor outcome — a potential non-immunological biomarker target in MCC.
For authoritative context on rare skin cancer epidemiology and treatment standards, see resources from the National Cancer Institute and NIH, which fund a significant portion of the academic research cited in this pipeline analysis.
Six Distinct Drug Modalities Across the MCC and Rare Skin Cancer Pipeline
From dominant PD-1/PD-L1 checkpoint blockade to MCC-specific epigenetic targeting and next-generation ADCs, the pipeline spans multiple mechanisms and development stages.
Anti-PD-1 / Anti-PD-L1 Monoclonal Antibodies
The most densely represented modality in the retrieved dataset, with more than 15 distinct patent filings across multiple jurisdictions. Regeneron Pharmaceuticals holds the largest single-assignee patent footprint, with numerous filings covering anti-PD-1 antibodies (including cemiplimab/REGN2810) for treating CSCC, BCC, and solid tumors in adjuvant and neoadjuvant settings. The mechanism involves blocking PD-1 and its ligands PD-L1/PD-L2, restoring cytotoxic T-cell activation. Anti-PD-L1 antibody therapy has entered clinical use for MCC specifically.
Clinical stage · Adjuvant, neoadjuvant, metastaticLSD1 (KDM1A) Epigenetic Inhibition
Dana-Farber Cancer Institute discloses that LSD1 inhibitors represent a novel targeted approach for MCC. LSD1 is a histone demethylase whose inhibition is proposed to suppress MCC tumor cell growth by altering epigenetic gene regulation. This is the only retrieved result focusing exclusively on a non-immunotherapy targeted mechanism for MCC. A complementary University of Canberra patent notes LSD1 overexpression drives epithelial-mesenchymal transition (EMT). The Dana-Farber filing is government-funded with NIH grant acknowledgment — a potentially licensable academic asset.
Preclinical / early translational · NIH-fundedAntibody-Drug Conjugates (ADCs)
Two ADC targets are identified: CD228 (melanotransferrin/p97), where Seattle Genetics holds multiple US and WO patents on anti-CD228 ADCs with explicit melanoma indications, enriched in advanced/metastatic and previously-treated populations; and AXL, where Genmab A/S discloses anti-AXL ADCs (HuMax-AXL-ADC/enapotamab vedotin) for melanoma in combination with MAPK pathway inhibitors. AXL expression increases in tumors resistant to PD-1/PD-L1 inhibitors, positioning AXL-ADC as a salvage strategy in checkpoint-refractory skin cancers.
Clinical investigation signalled · Resistant settingLAG-3 + PD-1 Combination Blockade
Bristol-Myers Squibb holds the most extensive combination therapy IP in this dataset, with multiple patent family members across CA, SG, IL, BR, MX, AU, and US for LAG-3 antagonist + PD-1 pathway inhibitor combination therapy in melanoma and unresectable tumors. The anti-LAG-3 antibody relatlimab with defined CDR sequences is explicitly claimed. This dual checkpoint approach is positioned as a first-line option in treatment-naïve metastatic or unresectable disease, with potential extension to other immunogenic skin cancers including MCC.
Clinical stage · Treatment-naïve metastaticSmall-Molecule PD-1/PD-L1 Immunomodulators
Bristol-Myers Squibb holds a patent for small-molecule immunomodulatory compounds of Formula (I) described as PD-1/PD-L1 pathway modulators. Separately, ChemoCentryx (now acquired by Amgen) discloses small molecules for treating PD-L1-expressing diseases via a Russian-jurisdiction patent. These represent early-stage structural chemistry claims with broad therapeutic scope, potentially complementary to antibody-based checkpoint blockade in MCC and related skin malignancies.
Preclinical / early · Broad therapeutic scopeTherapeutic RNA + Anti-PD-1 Combinations
Sanofi discloses therapeutic RNA agents in combination with anti-PD-1 antibodies for advanced solid tumors, including patients with PD-1/PD-L1 therapy resistance. This modality directly addresses the unmet need in MCC patients progressing on anti-PD-L1 therapy such as avelumab. The combination rationale targets innate and acquired checkpoint resistance and encompasses mucosal melanoma as a listed solid tumor indication, with patent language addressing patients who have "failed" checkpoint therapy.
Advanced preclinical / clinical · Checkpoint-refractoryPatent Filing Activity and Assignee Landscape in Rare Skin Cancer
Data derived from patent and literature records retrieved via PatSnap Eureka. All values reflect this dataset snapshot only.
Therapeutic Modality Distribution — Patent Filings in Dataset
Anti-PD-1/PD-L1 mAbs dominate with 15+ filings; LSD1 epigenetic and therapeutic RNA modalities represent early-stage white space.
Top Assignees by Patent Filing Volume in Dataset
Regeneron leads with 12+ filings across 9 jurisdictions; BMS holds the most extensive combination therapy IP; Dana-Farber holds the only MCC-specific epigenetic target patent.
Target-by-Target Evidence Summary from Patent and Literature Records
Each target below is sourced from retrieved patent or literature records. Development stage reflects language in patent claims — not independent clinical verification.
| Target | Modality | Key Assignee(s) | Relevance to MCC | Stage |
|---|---|---|---|---|
| PD-1 / PD-L1 / PD-L2 | Anti-PD-1/PD-L1 mAb (cemiplimab/REGN2810) | Regeneron, Janssen, Tesaro/GSK | Dominant axis; anti-PD-L1 in clinical use for MCC; PD-L1 heterogeneity documented | Clinical |
| LAG-3 | LAG-3 antagonist + PD-1 inhibitor (relatlimab) | Bristol-Myers Squibb | First-line metastatic melanoma; potential extension to MCC given immunogenic profile | Clinical |
| LSD1 (KDM1A) | Epigenetic inhibitor (histone demethylase) | Dana-Farber Cancer Institute | Only MCC-specific non-checkpoint target retrieved; NIH-funded; suppresses MCC tumor cell growth | Preclinical |
| AXL | ADC (enapotamab vedotin / HuMax-AXL-ADC) | Genmab A/S | Upregulated in checkpoint-resistant melanoma; salvage strategy for PD-1/PD-L1 refractory disease | Clinical |
| CD228 (Melanotransferrin) | Anti-CD228 ADC | Seattle Genetics / Seagen | Cancer-associated surface antigen; enriched in advanced/metastatic and previously-treated skin cancer | Clinical |
| G6PD | Prognostic biomarker | Nagoya City University | High G6PD predicts poor outcome in MCC independently of PD-L1; novel non-immunological signal | Translational |
| MEK / MAPK | PD-1 axis + MEK inhibitor combination | Genentech / F. Hoffmann-La Roche | MEK inhibition enhances tumor immunogenicity; evaluated in BRAF V600E, KRAS contexts | Preclinical |
Assess freedom-to-operate in the MCC IP landscape
Regeneron's portfolio across 9 jurisdictions creates significant FTO considerations for any new PD-1 entrant in CSCC, BCC, or MCC.
Six Convergent Combination Strategies Signalled in Patent Records
Retrieved results signal multiple combination strategies relevant to rare skin cancer and MCC treatment, from dual checkpoint blockade to immunoradiotherapy and epigenetic-immune crosstalk.
LAG-3 + PD-1 Dual Checkpoint Blockade
BMS's multi-jurisdiction LAG-3 + PD-1 patent family (relatlimab + nivolumab analogue) is among the best-supported combination strategies in the dataset, with explicit sequencing and dosing rationale. Positioned for treatment-naïve advanced melanoma but could extend to other immunogenic skin cancers including MCC.
PD-1 Axis + MEK Inhibitor
Genentech's patent portfolio on PD-1 axis + MEK inhibitor combinations includes data showing MEK inhibition enhances tumor immunogenicity, particularly in BRAF V600E, KRAS wildtype, and activating KRAS mutant contexts. May have translational relevance for rare MEK-dysregulated skin tumors.
AXL-ADC + BRAF/MEK Inhibitor Triplet
Genmab's AXL-ADC + dabrafenib/trametinib triplet combination is described with xenograft model data including Kaplan-Meier survival data in NRAS-mutant and BRAF inhibitor-resistant melanoma models, positioning AXL-ADC as a resistance-rescue agent alongside targeted therapy.
Therapeutic RNA + Anti-PD-1
Sanofi's filings describe therapeutic RNA agents for subjects who have become refractory to checkpoint inhibitors — directly addressing the unmet need in MCC patients progressing on anti-PD-L1 (e.g., avelumab). The combination rationale is explicitly patent-claimed for checkpoint-refractory advanced solid tumors.
IP White Space, FTO Risks, and First-Mover Opportunities in MCC
Regeneron's IP dominance in skin cancer PD-1 inhibition across at least 8 jurisdictions with multiple filing families creates significant freedom-to-operate considerations for any new anti-PD-1 entrant in CSCC, BCC, or MCC. Lifecycle management activity — neoadjuvant, adjuvant, and immunosuppressed patient claims — is expanding the patent estate beyond initial indications. For IP strategy support, PatSnap's IP analytics platform enables systematic FTO and landscape analysis.
MCC remains an underserved IP space. Aside from the Dana-Farber LSD1 filing and the Nagoya City University prognosis/biomarker patents, the retrieved dataset contains no other MCC-specific targeted therapy patents — suggesting significant white space for first-mover IP in MCC-dedicated mechanisms such as Merkel cell polyomavirus antigen targeting and somatostatin receptor targeting.
PD-L1 heterogeneity in MCC signals that standard PD-L1 companion diagnostics validated in other tumors may not be directly transferable to MCC, creating an opportunity for MCC-specific predictive biomarker development and IP. The LSD1 inhibitor approach from Dana-Farber — government-funded and NIH-supported — represents an academically-originated, potentially licensable asset specifically directed at MCC, a disease with very few targeted therapeutic options beyond checkpoint blockade.
For broader context on rare disease drug development strategy, see guidance from the FDA on orphan drug designation and from the European Patent Office on pharmaceutical patent lifecycle management. See how leading life sciences organisations use PatSnap to navigate complex IP landscapes like this one.
Five Translational Signals Identified Across Retrieved Patent Records
Explicit clinical trial efficacy outcome data, IND filing numbers, and regulatory submissions are not present in the retrieved records. Signals below are derived from patent claim language.
Cemiplimab (REGN2810) in CSCC and BCC — Adjuvant/Neoadjuvant Paradigms
Multiple Regeneron patents describe treating patients at high risk for disease recurrence post-surgery, explicitly using adjuvant and neoadjuvant PD-1 inhibitor paradigms — language consistent with active clinical trial contexts. A CN-jurisdiction patent references cemiplimab by brand identity (REGN2810) and IgG4P antibody class, indicating a clinically-characterised agent being lifecycle-managed. For life sciences IP analytics context, see PatSnap's life sciences solutions.
Adjuvant · Neoadjuvant · Lifecycle managementAnti-PD-L1 in MCC — Clinical Use Confirmed in Patent Record
The Nagoya City University patent (CN and JP jurisdictions) explicitly references "clinical use" of anti-PD-L1 antibody drugs in MCC having commenced, with data from primary vs. metastatic lesion PD-L1 expression supporting clinical correlative studies. This is one of the few retrieved records with direct MCC-specific clinical context.
Clinical use confirmed · MCC-specific dataLAG-3 + PD-1 in Melanoma — Treatment-Naïve Metastatic Patients
BMS filings consistently describe treatment-naïve metastatic or unresectable melanoma patients in human clinical contexts, with specified CDR sequences for relatlimab, consistent with a clinical-stage program. Multi-jurisdiction coverage (CA, SG, IL, BR, MX, AU, US) signals active commercialisation strategy.
Clinical stage · Multi-jurisdiction · First-lineTMB + MHC Expression as Biomarkers for PD-1 Inhibitor Patient Selection
A Regeneron patent (IL, 2023) describes selecting patients based on threshold levels of both tumor mutation burden (TMB) and MHC expression for PD-1 inhibitor treatment in skin cancer (CSCC, BCC) — a biomarker-guided patient selection strategy consistent with IND-enabling or ongoing trial work. This approach is relevant to MCC given the polyomavirus-driven vs. UV-driven immunogenic subsets.
Biomarker-guided · TMB + MHC thresholdsMerkel Cell Carcinoma Drug Pipeline — Key Questions Answered
PD-1/PD-L1 is the dominant therapeutic axis across rare and aggressive skin cancers, including MCC and CSCC. Retrieved results confirm that anti-PD-L1 antibody therapy has entered clinical use for MCC specifically, with more than 15 distinct patent filings across multiple jurisdictions addressed to PD-1 axis inhibition in skin cancers.
Unlike most cancers where high PD-L1 expression predicts poor prognosis, PD-L1 overexpression in MCC tumors is associated with favorable prognosis — a biologically distinctive feature that complicates standard biomarker interpretation. Additionally, PD-L1 expression in primary MCC lesions does not correlate with prognosis, but expression in cutaneous metastatic lesions shows strong correlation, underscoring intra-tumoral heterogeneity as a critical challenge in this disease.
Dana-Farber Cancer Institute discloses that LSD1 inhibitors represent a novel targeted approach for MCC. LSD1 is a histone demethylase whose inhibition is proposed to suppress MCC tumor cell growth by altering epigenetic gene regulation. This is the only retrieved result focusing exclusively on a non-immunotherapy targeted mechanism for MCC, representing an academically-originated, potentially licensable asset specifically directed at MCC.
Regeneron Pharmaceuticals is the highest-volume single assignee, with more than 12 distinct patent filings across US, EP, AU, CA, SG, IL, NZ, MX, and JP jurisdictions covering anti-PD-1 methods for CSCC, BCC, and solid tumors. Bristol-Myers Squibb holds the most extensive combination therapy IP in this dataset, with multiple family members for LAG-3 + PD-1 dual checkpoint approaches in melanoma.
Two ADC targets are identified: CD228 (melanotransferrin/p97), where Seattle Genetics holds multiple patents on anti-CD228 ADCs with explicit melanoma indications; and AXL, where Genmab A/S discloses anti-AXL ADCs (including HuMax-AXL-ADC/enapotamab vedotin) for melanoma in combination with MAPK pathway inhibitors. AXL receptor tyrosine kinase is implicated in acquired resistance to targeted therapy, providing a rationale for ADC-based intervention in the resistant setting.
MCC remains an underserved IP space: aside from the Dana-Farber LSD1 filing and the Nagoya City University prognosis/biomarker patents, the retrieved dataset contains no other MCC-specific targeted therapy patents — suggesting significant white space for first-mover IP in MCC-dedicated mechanisms such as Merkel cell polyomavirus antigen targeting and somatostatin receptor targeting. PD-L1 heterogeneity in MCC also signals that standard PD-L1 companion diagnostics validated in other tumors may not be directly transferable to MCC, creating an opportunity for MCC-specific predictive biomarker development and IP.
Still have questions? Let PatSnap Eureka search the MCC patent literature for you.
Ask PatSnap Eureka About MCCAccelerate Your MCC and Rare Skin Cancer Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to navigate complex drug pipelines, identify white space, and assess freedom-to-operate across global patent landscapes.
References
- Treating merkel cell carcinoma — Dana-Farber Cancer Institute, Inc., 2019, WO [Patent]
- Method for predicting prognosis of skin cancer and its use — Nagoya City University, 2025, JP [Patent]
- Prognosis prediction method for skin cancer and its use — Nagoya City University, 2022, CN [Patent]
- Administration of PD-1 inhibitors for treating skin cancer — Regeneron Pharmaceuticals, Inc., 2021, SG [Patent]
- Methods of treating skin cancer by administering a PD-1 inhibitor — Regeneron Pharmaceuticals, Inc., 2021, EP [Patent]
- Administration of a PD-1 inhibitor for treating skin cancer — Regeneron Pharmaceuticals, Inc., 2022, US [Patent]
- Methods of treating cancer by administering a PD-1 inhibitor — Regeneron Pharmaceuticals, Inc., 2023, IL [Patent]
- PD-1 inhibitor for use in a method of treating skin cancer — Regeneron Pharmaceuticals, Inc., 2025, IL [Patent]
- A method of determining risk for skin cancer development — Arizona Board of Regents, University of Arizona, 2022, US [Patent]
- Combination Therapy for Melanoma — Bristol-Myers Squibb Company, 2021, US [Patent]
- LAG-3 antagonist therapy for melanoma — Bristol-Myers Squibb Company, 2022, SG [Patent]
- Anti-CD228 antibodies and antibody-drug conjugates — Seattle Genetics, Inc., 2020, US [Patent]
- Anti-CD228 antibodies and antibody-drug conjugates — Seattle Genetics, Inc., 2020, WO [Patent]
- AXL-specific antibodies for cancer treatment — Genmab A/S, 2021, US [Patent]
- Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors — F. Hoffmann-La Roche AG, 2018, EP [Patent]
- Therapeutic RNA and Anti-PD1 antibodies for advanced stage solid tumor cancers — Sanofi, 2021, IL [Patent]
- Lysine-specific histone demethylase-1 inhibitors and uses thereof — University of Canberra, 2019, JP [Patent]
- Biomarkers for cancer therapeutics — Amgen Inc. / Merck Sharp & Dohme Corp., 2019, SG [Patent]
- Biomarkers for CD40 agonist therapy — Apexigen, Inc., 2023, WO [Patent]
- 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond — Istituto Nazionale Tumori, 2015 [Paper]
- National Cancer Institute — Rare Skin Cancer Resources
- National Institutes of Health — Funding for MCC and Skin Cancer Research
- U.S. Food and Drug Administration — Orphan Drug Designation and Rare Disease Guidance
- European Patent Office — Pharmaceutical Patent Lifecycle Management
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.